Research Article
Kidney Transplant Outcome Is Associated with Regulatory T Cell Population and Gene Expression Early after Transplantation
Table 1
Clinical characteristics of the transplant study groups.
| | Short term (prospective) | Long term (retrospective) | value |
| Recipient gender | 25 M/11 F | 27 M/13 F | 0.527 |
| Age at KTx | y (56; 46.5–62 y) | y (42; 27.5–52.5 y) | <0.001 |
| Age during the study | y (56; 46.5–62 y) | y (52; 37–59) | 0.153 |
| Time from KTx to examination | 1°: 3–5 days | y (7; 6–10 y) | <0.001 | 2°: 30–42 days | | | 3°: 90–123 days | | | 4°: 195–225 days | | | 5°: 365–443 days | | |
| RRT before tx | y (24; 14–33 y) | y (19; 12–29 y) | 0.398 |
| Donor gender | 26 M/10 F | 27 M/13 F | 0.423 |
| Donor age | y (53; 33–56.5 y) | y (45; 37–52 y) | 0.243 |
| HLA mismatches | From 1 to 6, median 4 | From 1 to 5, median 3 | |
| Panel-reactive antibodies (PRA) | 16 recipients (3–61%) | 19 recipients (4–50%) | |
| Cold ischemia time | h (24; 20–29 h) | h (24; 21–29 h) | 0.820 |
| Delayed graft function | 5 recipients | 6 recipients | 0.597 |
| Acute rejection episodes | 11 | 15 | 0.347 |
| Maintenance IS | Tac/MMF/steroids 20 | Tac/MMF/steroids 13 | | Tac/Aza/steroids 2 | Tac/Aza/steroids 1 | | CsA/MMF/steroids 13 | CsA/MMF/steroids 11 | | CsA/Aza/steroids 1 | CsA/Aza/steroids 15 | |
| 1-year eGFR | y (49; 42–60 y) | y (51, 40–60 y) | 0.844 |
|
|
Abbreviations: IS: immunosuppression; Tac: tacrolimus; MMF: mycophenolate mofetil or sodium; Aza: azathioprine; CsA: cyclosporine A.
|